WZ811

CAS No. 55778-02-4

WZ811( WZ811 | WZ-811 | WZ 811 )

Catalog No. M15027 CAS No. 55778-02-4

WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 32 In Stock
5MG 28 In Stock
10MG 35 In Stock
25MG 65 In Stock
50MG 104 In Stock
100MG 144 In Stock
200MG 183 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WZ811
  • Note
    Research use only, not for human use.
  • Brief Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WZ811 | WZ-811 | WZ 811
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR4
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    55778-02-4
  • Formula Weight
    290.36
  • Molecular Formula
    C18H18N4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 30 mg/mL (103.32 mM)
  • SMILES
    C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1
  • Chemical Name
    N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhan W, et al. J Med Chem, 2007, 50(23), 5655-5664.
molnova catalog
related products
  • MSX-130

    MSX-130 is CXCR4 Antagonist.

  • CHIR98014

    CHIR 98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.

  • Syringaresinol-di-O-...

    1. Syringaresinol-di-O-glucoside protects the animals from the stress-induced decreases in sex behaviours and in rectal temperature, the stress-induced failure of retrieval of memory, and the stress-induced enlargement of adrenal gland.